Drug intelligence / Profile preview

NMS-PDC

Development stage: Preclinical
Lead developer: Italfarmaco
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

NMS-PDC is a preclinical-stage peptide-drug conjugate (PDC) platform developed by Nerviano Medical Sciences (NMS), a member of the NMS Group. This technology involves the conjugation of a targeting peptide to a potent cytotoxic payload via a stable linker. The small molecular size of the peptide carrier is designed to facilitate superior tumor penetration and more rapid systemic clearance compared to larger antibody-drug conjugates (ADCs), potentially improving the therapeutic index and reducing off-target toxicities. NMS has established non-exclusive partnerships to leverage this platform for the development of PDCs against various undisclosed oncology targets.

Other names: peptide drug conjugate-NMSCMS-PDCNerviano Peptide Drug Conjugate

Beyond the preview

Go deeper on NMS-PDC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMS-PDC.

Explore the full profile